<ul>
<li>MarketBeat 評選的五大高評級小型股</li>
</ul>
<p>Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）- HC Wainwright 的股票研究人員在 5 月 6 日向客户和投資者發佈的研究報告中下調了對 Trevi Therapeutics 的 2030 財年收益預期。HC Wainwright 分析師 B. Folkes 現在預測該公司將發佈每股收益 0.70 美元，低於之前預測的 0.79 美元。HC Wainwright 目前對該股票的評級為 “買入”，目標價格為 21.00 美元。市場普遍預期 Trevi Therapeutics 當前全年的收益為每股（0.46）美元。</p>
<p>獲取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
<p>其他股票分析師最近也對該公司發佈了報告。摩根士丹利在週三的研究報告中重申了對 Trevi Therapeutics 的 “增持” 評級，並給出了 20.00 美元的目標價格。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Trevi Therapeutics 的 “賣出（d-）” 評級。Needham &amp; Company LLC 在週三的研究報告中將 Trevi Therapeutics 的目標價格從 24.00 美元下調至 23.00 美元，並對該股票給予 “買入” 評級。JonesTrading 在 3 月 19 日的研究報告中將 Trevi Therapeutics 的目標價格從 25.00 美元下調至 24.00 美元，並對該股票給予 “買入” 評級。最後，D. Boral Capital 在 4 月 17 日的研究報告中重申了 “買入” 評級，並給出了 19.00 美元的目標價格。兩位分析師對該股票給予了強烈買入評級，九位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “買入”，共識目標價格為 21.70 美元。</p>
<p><strong>查看我們關於 Trevi Therapeutics 的最新股票報告</strong></p>
<h2>Trevi Therapeutics 股票下跌 2.7%</h2>
<p>週四，TRVI 股票開盤價為 14.26 美元。該公司的 50 日移動平均價格為 12.63 美元，200 日移動平均價格為 11.92 美元。該公司的市值為 18.3 億美元，市盈率為-44.56，貝塔值為 1.07。Trevi Therapeutics 的 52 周低點為 5.38 美元，52 周高點為 16.12 美元。</p>
<p>Trevi Therapeutics（NASDAQ:TRVI - 獲取免費報告）最近在 5 月 5 日宣佈了其季度收益結果。該公司報告季度每股收益（0.09）美元，低於分析師的共識預期（0.07）美元，差距為（0.02）美元。</p>
<h2>對 Trevi Therapeutics 的對沖基金看法</h2>
<p>一些機構投資者最近買入和賣出了該股票的股份。中國環球資產管理有限公司在第三季度將其在 Trevi Therapeutics 的持股增加了 4.5%。中國環球資產管理有限公司現在擁有 21,346 股該公司的股票，價值 195,000 美元，在此期間又購買了 911 股。Hilton Head Capital Partners LLC 在第一季度將其在 Trevi Therapeutics 的持股增加了 32.6%。Hilton Head Capital Partners LLC 現在擁有 4,250 股該公司的股票，價值 51,000 美元，在此期間又購買了 1,044 股。Ameritas Investment Partners Inc.在第三季度將其在 Trevi Therapeutics 的持股增加了 20.5%。Ameritas Investment Partners Inc.現在擁有 7,632 股該公司的股票，價值 70,000 美元，在此期間又購買了 1,300 股。Kennedy Capital Management LLC 在第四季度將其在 Trevi Therapeutics 的持股增加了 2.4%。Kennedy Capital Management LLC 現在擁有 56,269 股該公司的股票，價值 704,000 美元，在此期間又購買了 1,336 股。最後，未來資產全球投資有限公司在第四季度將其在 Trevi Therapeutics 的持股增加了 32.3%。未來資產全球投資有限公司現在擁有 6,231 股該公司的股票，價值 78,000 美元，在此期間又購買了 1,523 股。95.76% 的股票由機構投資者持有。</p>
<h2>關於 Trevi Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Trevi Therapeutics, Inc 是一家臨牀階段的生物製藥公司，專注於開發新型非阿片類療法以管理慢性和急性疼痛。該公司利用專有藥物遞送平台和靶向分子方法來解決癌症相關疼痛、化療引起的神經病和其他嚴重疼痛狀況中的高未滿足需求。</p>
<p>其主要產品候選藥物是一種專有的河豚毒素（TTX）配方，這是一種鈉通道阻滯劑，正在早期臨牀試驗中評估用於與晚期癌症和外周神經病相關的中度至重度疼痛。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Trevi Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Trevi Therapeutics 嗎？</h2>
<p>在考慮 Trevi Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Trevi Therapeutics 並不在名單上。</p>
<p>雖然 Trevi Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TRVI

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

DWA 醫療保健動量 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

美國制藥 ETF - iShares

醫藥 3 倍做多 - Direxion

醫療業 ETF - SPDR

<p>HC Wainwright 的股票研究員將 Trevi Therapeutics (NASDAQ:TRVI) 的 2030 財年每股收益預期從 0.79 美元下調至 0.70 美元。該公司維持 “買入” 評級，目標價為 21.00 美元。其他分析師的看法各異，摩根士丹利和 Needham & Company 也給予買入評級，但目標價不同。Trevi 的股票最近下跌了 2.7%，開盤價為 14.26 美元，市值為 18.3 億美元。該公司專注於開發非阿片類的疼痛管理療法</p>

<ul>
<li>MarketBeat’s Top 5 Rated Small-Cap Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 評選的五大高評級小型股</li>
</ul>
</div><p>Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright decreased their FY2030 earnings estimates for Trevi Therapeutics in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.70 per share for the year, down from their prior forecast of $0.79. HC Wainwright currently has a &#34;Buy&#34; rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.46) per share.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）- HC Wainwright 的股票研究人員在 5 月 6 日向客户和投資者發佈的研究報告中下調了對 Trevi Therapeutics 的 2030 財年收益預期。HC Wainwright 分析師 B. Folkes 現在預測該公司將發佈每股收益 0.70 美元，低於之前預測的 0.79 美元。HC Wainwright 目前對該股票的評級為 “買入”，目標價格為 21.00 美元。市場普遍預期 Trevi Therapeutics 當前全年的收益為每股（0.46）美元。</p>
</div><p>Get <strong>Trevi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
</div><p>Other equities analysts also recently issued reports about the company. Morgan Stanley restated an &#34;overweight&#34; rating and issued a $20.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Needham &amp; Company LLC dropped their price target on Trevi Therapeutics from $24.00 to $23.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday. JonesTrading dropped their price target on Trevi Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 19th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Buy&#34; and a consensus target price of $21.70.</p>
<div class="lb-trans"><p>其他股票分析師最近也對該公司發佈了報告。摩根士丹利在週三的研究報告中重申了對 Trevi Therapeutics 的 “增持” 評級，並給出了 20.00 美元的目標價格。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Trevi Therapeutics 的 “賣出（d-）” 評級。Needham &amp; Company LLC 在週三的研究報告中將 Trevi Therapeutics 的目標價格從 24.00 美元下調至 23.00 美元，並對該股票給予 “買入” 評級。JonesTrading 在 3 月 19 日的研究報告中將 Trevi Therapeutics 的目標價格從 25.00 美元下調至 24.00 美元，並對該股票給予 “買入” 評級。最後，D. Boral Capital 在 4 月 17 日的研究報告中重申了 “買入” 評級，並給出了 19.00 美元的目標價格。兩位分析師對該股票給予了強烈買入評級，九位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “買入”，共識目標價格為 21.70 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Trevi Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Trevi Therapeutics 的最新股票報告</strong></p>
</div><h2>Trevi Therapeutics Stock Down 2.7%</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 股票下跌 2.7%</h2>
</div><p>Shares of TRVI stock opened at $14.26 on Thursday. The company has a 50 day moving average price of $12.63 and a 200-day moving average price of $11.92. The firm has a market capitalization of $1.83 billion, a PE ratio of -44.56 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12.</p>
<div class="lb-trans"><p>週四，TRVI 股票開盤價為 14.26 美元。該公司的 50 日移動平均價格為 12.63 美元，200 日移動平均價格為 11.92 美元。該公司的市值為 18.3 億美元，市盈率為-44.56，貝塔值為 1.07。Trevi Therapeutics 的 52 周低點為 5.38 美元，52 周高點為 16.12 美元。</p>
</div><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02).</p>
<div class="lb-trans"><p>Trevi Therapeutics（NASDAQ:TRVI - 獲取免費報告）最近在 5 月 5 日宣佈了其季度收益結果。該公司報告季度每股收益（0.09）美元，低於分析師的共識預期（0.07）美元，差距為（0.02）美元。</p>
</div><h2>Hedge Funds Weigh In On Trevi Therapeutics</h2>
<div class="lb-trans"><h2>對 Trevi Therapeutics 的對沖基金看法</h2>
</div><p>A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company's stock worth $195,000 after purchasing an additional 911 shares during the period. Hilton Head Capital Partners LLC raised its holdings in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company's stock worth $51,000 after purchasing an additional 1,044 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after purchasing an additional 1,300 shares during the period. Kennedy Capital Management LLC raised its holdings in Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company's stock valued at $704,000 after acquiring an additional 1,336 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company's stock valued at $78,000 after acquiring an additional 1,523 shares during the period. 95.76% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近買入和賣出了該股票的股份。中國環球資產管理有限公司在第三季度將其在 Trevi Therapeutics 的持股增加了 4.5%。中國環球資產管理有限公司現在擁有 21,346 股該公司的股票，價值 195,000 美元，在此期間又購買了 911 股。Hilton Head Capital Partners LLC 在第一季度將其在 Trevi Therapeutics 的持股增加了 32.6%。Hilton Head Capital Partners LLC 現在擁有 4,250 股該公司的股票，價值 51,000 美元，在此期間又購買了 1,044 股。Ameritas Investment Partners Inc.在第三季度將其在 Trevi Therapeutics 的持股增加了 20.5%。Ameritas Investment Partners Inc.現在擁有 7,632 股該公司的股票，價值 70,000 美元，在此期間又購買了 1,300 股。Kennedy Capital Management LLC 在第四季度將其在 Trevi Therapeutics 的持股增加了 2.4%。Kennedy Capital Management LLC 現在擁有 56,269 股該公司的股票，價值 704,000 美元，在此期間又購買了 1,336 股。最後，未來資產全球投資有限公司在第四季度將其在 Trevi Therapeutics 的持股增加了 32.3%。未來資產全球投資有限公司現在擁有 6,231 股該公司的股票，價值 78,000 美元，在此期間又購買了 1,523 股。95.76% 的股票由機構投資者持有。</p>
</div><h2>About Trevi Therapeutics</h2>
<div class="lb-trans"><h2>關於 Trevi Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc 是一家臨牀階段的生物製藥公司，專注於開發新型非阿片類療法以管理慢性和急性疼痛。該公司利用專有藥物遞送平台和靶向分子方法來解決癌症相關疼痛、化療引起的神經病和其他嚴重疼痛狀況中的高未滿足需求。</p>
</div><p>Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.</p>
<div class="lb-trans"><p>其主要產品候選藥物是一種專有的河豚毒素（TTX）配方，這是一種鈉通道阻滯劑，正在早期臨牀試驗中評估用於與晚期癌症和外周神經病相關的中度至重度疼痛。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Trevi Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Trevi Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=TRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Trevi Therapeutics 嗎？</h2>
</div><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Trevi Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Trevi Therapeutics 並不在名單上。</p>
</div><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Trevi Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Research Analysts Set Expectations for TRVI FY2030 Earnings

Market Beat

Trevi Therapeutics

摩根士丹利

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Weis Markets

卡爾蔡司

NEUBERGER BERMAN REAL ES-W/I

Landbridge Co LLC

Chemours

New England Real Asso

Jewett-Cameron

TJX零售

TJGC

D. BORAL ARC ACQUISITION I CORP. C/WTS 23/07/2030(TO PUR COM)

D Boral ARC Acquisition I

D Boral ARC Acquisition I - Unit

中國光大控股

Arcadian Asset

SC ASSETS HLDGS - D

Rit Capital Partners PLC

Hennessy Capital Investment Corp VII

Hennessy Capital Investment Corp VII - Unit

Virtus投資

Artisan合夥資產管理

VGI Partners Global Investments Ltd.

Kennedy-Wilson控股

Annaly資本管理

Sun Capital Management Corp.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

中國光大水務

光大永年

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

研究分析師設定了對 Trevi Therapeutics 2030 財年收益的預期